



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

February 15, 2022 6:30 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**

- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- **DVHA Pharmacy Administration Updates** **6:40 - 6:45**

- **Medical Director Update** **6:45 - 6:50**

- **Follow-up Items from Previous Meetings** **6:50 – 6:50**

- **RetroDUR/ProDUR** **6:50- 7:20**
 - Data presentation: Immunologic Therapies for Asthma
 - Introduce: Letrozole Use for Infertility

- **Clinical Update: Drug Reviews** **7:20-7:55**
(Public comment prior to Board action)
 - Biosimilar Drug Reviews**
 - None at this time.

 - Full New Drug Reviews**
(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)
 - Azstarys® (serdexmethylphenidate and dexmethylphenidate)
 - Brexafemme® (ibrexafungerp)
 - Bylvay® (obevoxibat)
 - Kerendia® (finerenone)
 - Kloxxado® (naloxone hydrochloride nasal spray)
 - Rezurock® (belumosudil)
 - Saphnelo® (anifrolumab-fnia)

- **New Managed Therapeutic Drug Classes** **7:55 -7:55**
 - None at this time
(Public comment prior to Board action)
 - None at this time

- **Therapeutic Drug Classes – Periodic Review** **7:55 - 8:25**
(Public comment prior to Board action)
 - Antibiotics, Cephalosporins
 - Antibiotics, Fluoroquinolones
 - Antibiotics, GI (new drug Aemcolo® (rifamycin) included)
 - Antibiotics, Miscellaneous
 - Antibiotics, Tetracyclines
 - Antiretrovirals
 - Antivirals, Oral
 - Antivirals, Topical
 - Skeletal Muscle Relaxants

- **Review of Newly Developed/Revised Criteria** **8:25 - 8:30**
(Public comment prior to Board action)
 - None at this time

- **General Announcements** **8:30 – 8:30**

- **Adjourn** **8:30**